文献速递前列腺增生与排尿功能障碍

骶神经调控与A型肉毒毒素治疗膀胱过度活动症的真实世界表现:聚焦安全性与费用

Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
PubMed 文献 · J Urol · 2019-07-26

基于纽约州SPARCS数据库2013—2016年2680例接受三线治疗(骶神经调控1328例、A型肉毒毒素1352例)的膀胱过度活动症患者队列,比较30天安全事件及1年、3年医疗费用。A型肉毒毒素组尿路感染、血尿、尿潴留及急诊就诊风险高于骶神经调控组;A型肉毒毒素费用低于骶神经调控装置(1年2896美元vs 15343美元,3年3454美元vs 16189美元,各p<0.01)。

要点

  • 骶神经调控植入1年内15.8%、3年内26.1%需再次干预。
  • A型肉毒毒素组尿路感染、血尿、尿潴留及急诊就诊风险高于骶神经调控组。
  • A型肉毒毒素费用低于骶神经调控装置(1年2896美元vs 15343美元,3年3454美元vs 16189美元,各p<0.01)。

核心结论

  • 骶神经调控植入比A型肉毒毒素注射更昂贵,但接受骶神经调控的患者并发症发生率低于接受A型肉毒毒素治疗的患者。
  • 作者提出需建立质量改进集合数据库以追踪A型肉毒毒素与骶神经调控治疗信息,从而为患者和医生决策提供更好的表现与比较数据。

研究设计与样本

  • 全纳入、基于人群的队列研究,使用纽约州SPARCS系统中全州手术数据,纳入2013年1月1日至2016年12月31日接受三线治疗(骶神经调控或A型肉毒毒素)的膀胱过度活动症患者2680例,其中骶神经调控1328例、A型肉毒毒素1352例。
  • 采用倾向性评分匹配控制混杂因素,并进行安全事件的比较分析。

主要发现

  • 平均±SD年龄61.7±16.3岁,82.7%为女性。
  • 骶神经调控植入1年内15.8%的病例需再次干预,3年内为26.1%。
  • 在比较分析中,与骶神经调控组相比,接受A型肉毒毒素治疗的患者尿路感染、血尿、尿潴留及急诊就诊风险更高。
  • A型肉毒毒素总体费用低于骶神经调控装置费用(1年2896美元vs 15343美元,3年3454美元vs 16189美元,各p<0.01)。

临床怎么用

  • 作者认为,需建立质量改进集合数据库以追踪A型肉毒毒素与骶神经调控治疗信息,从而为患者和医生决策提供更好的表现与比较数据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to determine the real world safety and cost of third line overactive bladder therapies, including onabotulinumtoxinA and sacral neuromodulation. MATERIALS AND METHODS: We performed an all-inclusive, population based cohort study of third line therapies of overactive bladder (sacral neuromodulation or onabotulinumtoxinA) using the statewide surgical data captured in the New York Statewide Planning and Research Cooperative System. The main outcome measures were 30-day safety events, and 1 and 3-year health care utilization costs. Propensity score matching was done to control for confounding factors and comparative analyses of safety events were also performed. RESULTS: Our cohort included 2,680 patients, of whom 1,328 underwent sacral neuromodulation and 1,352 received onabotulinumtoxinA from January 1, 2013 through December 31, 2016. Average ± SD age was 61.7 ± 16.3 years and 82.7% of the patients were female. Sacral neuromodulation implantation led to re-intervention in 15.8% of cases within 1 year and in 26.1% at 3 years. In this comparative analysis patients who received onabotulinumtoxinA therapy were at higher risk for urinary tract infection, hematuria, urinary retention and an emergency room visit compared to those treated with sacral neuromodulation. The overall cost of onabotulinumtoxinA was lower than the cost of the sacral neuromodulation device (cost at 1 year $2,896 vs $15,343 and at 3 years $3,454 vs $16,189, each p <0.01). CONCLUSIONS: Sacral neuromodulation implantation was more expensive than onabotulinumtoxinA injection. However, patients who underwent sacral neuromodulation had a lower complication rate than patients treated with onabotulinumtoxinA. A quality improvement collective database must be created to track information on onabotulinumtoxinA and sacral neuromodulation treatment. This would help generate better performance and comparative data for patient and physician decision making.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chughtai B, Clemens JQ, Thomas D, et al. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost. J Urol. 2019. PMID: 31347949. doi:10.1097/JU.0000000000000462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。